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Pancreatic islet transplantation is a highly promising approach for the treatment of insulin-
dependent diabetes mellitus. However, the procedure remains experimental for several 
reasons, including its low efficiency caused by the early graft loss of transplanted islets. 
We demonstrate that Gr-1
 
 
 
CD11b
 
 
 
 cells generated by transplantation and their IFN-
 
 
 
 
production triggered by V
 
 
 
14 NKT cells are an essential component and a major cause of 
early graft loss of pancreatic islet transplants. Gr-1
 
 
 
CD11b
 
 
 
 cells from V
 
 
 
14 NKT cell–
deficient (
 
J
 
 
 
281
 
 
 
/
 
 
 
) mice failed to produce IFN-
 
 
 
, resulting in efficient islet graft 
acceptance. Early graft loss was successfully prevented through the repeated administration 
of 
 
 
 
-galactosylceramide, a specific ligand for V
 
 
 
14 NKT cells, resulting in dramatically 
reduced IFN-
 
 
 
 production by Gr-1
 
 
 
CD11b
 
 
 
 cells, as well as V
 
 
 
14 NKT cells. Our study 
elucidates, for the first time, the crucial role of Gr-1
 
 
 
CD11b
 
 
 
 cells and the IFN-
 
 
 
 they 
produce in islet graft rejection and suggests a novel approach to improving transplantation 
efficiency through the modulation of V
 
 
 
14 NKT cell function.
 
Patients with insulin-dependent diabetes melli-
tus  regularly fail to achieve insulin indepen-
dence after transplantation of islets from a single
donor pancreas because of early graft loss (1,
2). Early islet loss is estimated to occur in
 
 
 
50% of the transplanted islet mass (3) and
occurs at similar frequencies in both allogeneic
and syngeneic combinations in a mouse model,
possibly because of stress, inflammation, or in-
nate responses caused by transplantation. To
analyze the mechanisms of early islet loss, the
syngeneic islet transplantation model is ad-
vantageous because allogeneic immune re-
sponses are avoidable.
After transplantation into the recipient liver,
islet grafts are lodged together in the periphery
of the portal vein as emboli, causing ischemic
degeneration of the corresponding areas. This
may trigger innate immune responses resulting
in the release of inflammatory cytokines harmful
to islet grafts. Insulin-secreting 
 
 
 
 cells have
been shown to be susceptible in vitro to expo-
sure to proinflammatory cytokines such as
IFN-
 
 
 
, TNF-
 
 
 
, and IL-1
 
 
 
 (4), and it is likely
that proinflammatory cytokines are also a major
cause of islet graft failure in vivo.
V
 
 
 
14 NKT cells belong to a distinct subset
of lymphocytes bridging the innate and acquired
immune systems and play an important role in
the immediate responses, because V
 
 
 
14 NKT
cells produce large amounts of IFN-
 
 
 
 immedi-
ately after activation, which in turn activates
NK cells and other cells in the innate immune
system and CD4 Th1 cells and CD8 cytotoxic
T cells in the acquired immune system (5–9).
Thus, V
 
 
 
14 NKT cells serve as a front line de-
fense against various bacteria, viruses, fungi, and
intracytoplasmic parasites (5, 6).
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Because V
 
 
 
14 NKT cells are relatively abundant in the
liver, the site of choice for islet transplantation, and because
IFN-
 
 
 
 is believed to be an important factor in the destruc-
tion of islet 
 
 
 
 cells, we hypothesized that V
 
 
 
14 NKT cells in
the liver might be involved in islet graft failure. We demon-
strate that, in mice, IFN-
 
 
 
–producing Gr-1
 
 
 
CD11b
 
 
 
 cells
and V
 
 
 
14 NKT cells are major components of the early
graft loss of transplanted islets and the low efficiency of pan-
creatic islet transplants. Our findings provide an approach to
improve transplant efficiency through the modulation of
V
 
 
 
14 NKT cell function.
 
RESULTS AND DISCUSSION
V
 
 
 
14 NKT cells are responsible for early islet graft loss
 
To test the possibility that V
 
 
 
14 NKT cells are involved in
islet graft failure, we attempted to establish an experimental
system of islet transplantation. We first examined the mini-
mum number of donor islets required to ameliorate hyper-
glycemia in streptozotocin (STZ)-induced diabetic mice.
C57BL/6 mice became hyperglycemic and diabetic soon af-
ter the i.v. injection of STZ (Fig. 1 A). In STZ-induced dia-
betic mice, 400 syngeneic islets transplanted into the liver
were found to be sufficient to achieve normoglycemia (Fig.
1 B, left), whereas normoglycemia could not be achieved by
the transplantation of 200 syngeneic islets, the number of is-
lets that can be isolated from a single mouse pancreas (Fig. 1
C, left). In agreement with biochemical data, intact islets
with well-granulated 
 
 
 
 cells were histologically seen in mice
receiving 400 islets, whereas damaged islets with degranu-
lated 
 
 
 
 cells were observed in mice receiving 200 islets (Fig.
1, B and C, right).
We then investigated whether V
 
 
 
14 NKT cells are in-
volved in early islet graft loss. All diabetic J
 
 
 
281
 
 
 
/
 
 
 
 mice be-
came normoglycemic by day 11 after transplantation of 200
or even 100 islets (Fig. 1, D and E, left). Histological exami-
nation also clearly demonstrated the existence of intact islet
grafts with well-granulated 
 
 
 
 cells (Fig. 1 D, right), suggest-
ing that V
 
 
 
14 NKT cells are responsible for graft rejection
of transplanted islets.
To prove the deleterious effects of V
 
 
 
14 NKT cells on
grafted islets, 5 
 
 
 
 10
 
6
 
 liver mononuclear cells isolated from
naive WT, J
 
 
 
281
 
 
 
/
 
 
 
, or IFN-
 
 
 
–deficient mice were in-
jected at the time of transplantation into the portal vein of
diabetic J
 
 
 
281
 
 
 
/
 
 
 
 mice receiving 200 syngeneic islets. Dia-
betic J
 
 
 
281
 
 
 
/
 
 
 
 mice injected with cells from WT mice re-
mained hyperglycemic 60 d after transplantation (Fig. 1 F,
left), whereas those with cells from J
 
 
 
281
 
 
 
/
 
 
 
 or IFN-
 
 
 
–defi-
cient mice became normoglycemic (Fig. 1, G and H, left).
Histological examination also proved the existence of intact
islets in the recipients of cells from J
 
 
 
281
 
 
 
/
 
 
 
 or IFN-
 
 
 
–defi-
cient mice, but not from WT mice (Fig. 1, F–H, right). The
results suggest that V
 
 
 
14 NKT cells and IFN-
 
 
 
 are essential
components of early graft failure.
 
Gr-1
 
 
 
CD11b
 
 
 
 cells induced by transplantation are effector 
cells for early graft loss
 
To elucidate cellular changes associated with islet graft fail-
ure, hepatic mononuclear cells were isolated periodically af-
ter islet transplantation and examined by FACS using
 
 
 
-galactosylceramide (
 
 
 
-GalCer)–loaded CD1d (
 
 
 
-GalCer–
CD1d) tetramers. FACS analysis showed that the percentage
of 
 
 
 
-GalCer–CD1d tetramer
 
 
 
 V
 
 
 
14 NKT cells initially de-
creased from 10.3% at 0 h to 
 
 
 
5% at 6 h but then surged to
19.2% at 24 h after islet transplantation (Fig. 2 A, left). The
findings indicate the activation of V
 
 
 
14 NKT cells that
down-modulate their receptor expression, resulting in the
failure to detect V 14 NKT cells by  -GalCer–CD1d tetra-
mers, as reported previously (10–12). Furthermore, V 14
Figure 1. V 14 NKT cells are responsible for the early loss of syn-
geneic islet grafts. (A) Hyperglycemia in C57BL/6 mice after i.v. injection 
with STZ. (B) Normoglycemia in STZ-induced diabetic mice transplanted with 
400 islets. (C) Hyperglycemia in STZ-induced diabetic mice transplanted 
with 200 islets. (D and E) Normoglycemia in STZ-induced diabetic J 281 /  
mice transplanted with 200 (D) or 100 (E) islets. (F–H) STZ-induced diabetic 
J 281 /  mice transplanted with 200 islets were injected i.p. with 5   106 
hepatic mononuclear cells from WT (F), J 281 /  (G), or INF- –deficient 
(H) mice. Individual lines represent the nonfasting plasma glucose levels of 
each animal (left panels). The difference in the rate of euglycemia in diabetic 
WT mice after transplantation of 400 (n   6) or 200 (n   10) islets is 
statistically significant (P   0.001). The asterisks indicate that the animals 
died because of severe diabetes. The right panels show photomicrographs 
of islet grafts in the liver examined on day 60 after transplantation. HE, 
hematoxylin and eosin; AF, aldehyde fuchsin. Original magnification   100.JEM VOL. 202, October 3, 2005 915
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NKT cells obtained at 2–6 h after transplantation produced
inflammatory cytokines, such as IFN-  and IL-1  (Fig. 2 A),
suggesting that V 14 NKT cells are activated by transplanta-
tion. After the disappearance of V 14 NKT cells, V 14
NKT cells expand rapidly, as shown in Fig. 2 A (24 h) and as
previously reported (10–12). Interestingly, the proportion of
 -GalCer–CD1d tetramer  cells producing high levels of
INF-  increased markedly from 0.5 to 14.3% at 6 h after is-
let transplantation (Fig. 2 A, left). The  -GalCer–CD1d
tetramer  cells were further gated, analyzed for Gr-1 and
CD11b expression in relation to IFN-  production, and de-
termined to be Gr-1 CD11b  cells (Fig. 2 B). Gr-1 
CD11b  cells were CD11c , CD86 , MHC class II ,
F4/80 / , and CD68 /  (Fig. 2 C) and were neutrophils in
morphology (Fig. 2 D), indicating that these cells are neu-
trophils. The neutrophils that infiltrated the transplanted islet
(Fig. 2 D) are likely to be the effector cells, because the in-
jection of antibodies against Gr-1 or CD11b prevented the
rejection of islet transplants (Fig. 3).
In marked contrast to WT mice, the increase in IFN- –
producing Gr-1 CD11b  cells was not seen in J 281 / 
mice (Fig. 2 A, left), suggesting that the activation of V 14
NKT cells after islet transplantation triggers the induction of
IFN-  production by Gr-1 CD11b  cells. Note that no in-
crease in IL-4–producing cells was observed regardless of the
presence or absence of V 14 NKT cells (Fig. 2 A, right).
It is well known that soon after activation with  -GalCer
or IL-12, V 14 NKT cells produce IFN- , which, in turn,
stimulates IFN-  secretion by other cells, such as NK cells or
CD8 T cells (9, 13, 14). In fact, a single injection of  -GalCer
dramatically augmented IFN-  production in Gr-1 CD11b 
cells (see Fig. 5 D), suggesting that V 14 NKT cells indeed ac-
tivate Gr-1 CD11b  cells to produce IFN- . It is thus likely
that increased IFN-  production by Gr-1 CD11b  cells is a
direct consequence of V 14 NKT cell activation triggered by
islet transplantation, although molecules responsible for the ac-
tivation of V 14 NKT cells remain to be determined.
Similar to IFN- –producing Gr-1 CD11b  cells, IL-4–
producing Gr-1 CD11b  cells induced by aluminum hy-
anti–IL-4 (right). Gated CD3  -GalCer–CD1d tetramer  cells (solid line) 
were also investigated for their IFN-  production compared with the 
negative control (dotted line). (B) IFN- –producing Gr-1 CD11b  cells. 
 -GalCer–CD1d tetramer  cells from the livers of naive mice (top) and 
mice 6 h after the transplantation of 200 syngenic islets (bottom) were 
further gated (left) and analyzed for Gr-1 (PerCP) and CD11b (FITC) expression 
in relation to IFN-  production by intracytoplasmic staining (middle and 
right). (C) Surface phenotypes of Gr-1 CD11b  cells.  -GalCer–CD1d 
tetramer  cells in B were further analyzed by FACS. Their surface expression 
(solid line) was compared with the control (dotted line). The numbers in B 
represent the percentages of cells in the corresponding areas. Representative 
data from two to three experiments are shown. (D) Histological findings 
of Gr-1 CD11b  cells isolated from the liver 6 h after transplantation. 
(i) May-Grunwald-Giemsa staining. Original magnification   500. 
(ii–iv) Immunohistochemical staining on insulin (ii), Gr-1 (iii), and F4/80 
(iv). The arrowheads indicate infiltrated Gr-1  cells into the transplanted 
islet. Original magnification   400.
Figure 2. INF- –producing Gr-1 CD11b  cells generated after 
syngeneic islet transplantation. (A) Requirement of V 14 NKT cells for 
induction of IFN- –producing cells. Liver mononuclear cells isolated from 
WT or J 281 /  mice 2, 6, and 24 h after the transplantation of 200 islets 
were examined by FACS with PE– -GalCer–CD1d tetramers and allophy-
cocyanin-conjugated anti–IFN-  (left) or allophycocyanin-conjugated PREVENTION OF EARLY LOSS OF SYNGENEIC TRANSPLANTED ISLETS | Yasunami et al. 916
droxide, when antigens precipitated by aluminum hydroxide
are used for immunization, play an important role in B cell
activation (15). Despite the similarities in antigen indepen-
dence and importance in the immune responses of these two
populations, several apparent differences are noted, such as
the fact that IL-4–producing Gr-1 CD11b  cells are evident
6 d after immunization, whereas IFN- –producing Gr-
1 CD11b  cells appear soon (6 h) after transplantation. The
findings suggest functional diversity, although it is unclear
whether the two populations are the same or different cells
producing different cytokines at different time points.
Prevention of early graft loss by modulation of V 14 
NKT cell function
In agreement with previously reported data (16), V 14 NKT
cells secreted large amounts of IFN-  immediately after stim-
ulation with  -GalCer but stopped producing IFN-  after re-
peated  -GalCer stimulation (Fig. 4 A). Therefore, we hy-
pothesized that repeated  -GalCer injections would modify
IFN-  production by V 14 NKT cells and thus affect graft
survival. To test this possibility, STZ-induced diabetic WT
mice that had received 400 islets were treated once with vehi-
cle at the time of transplantation; all mice became normogly-
cemic (Fig. 4 B). When diabetic WT mice that had received
400 islets were treated with a single 100- g/kg injection of
 -GalCer, none of the mice became normoglycemic even 60 d
after transplantation (Fig. 4 C). In contrast, when WT mice
were treated three times with 100  g/kg  -GalCer on days
15, 11, and 7 before the induction of diabetes before islet
transplantation, the transplantation of only 200 islets restored
normoglycemia in all recipient mice within 10 d (Fig. 4 E).
Mice treated with vehicle instead of  -GalCer remained hy-
perglycemic (Fig. 4 D). In agreement with our prediction, the
results demonstrated that repeated  -GalCer injections before
islet transplantation resulted in the down-regulation of IFN- 
production, which positively affected islet engraftment.
IFN-  production by Gr1 CD11b  cells that were triggered 
by V 14 NKT cells
We investigated the effect of  -GalCer on the production of
IFN-  by Gr-1 CD11b  cells. FACS analysis revealed that
Gr-1 CD11b  cells expanded rapidly after islet transplanta-
tion (Fig. 5 B) compared with nontransplanted controls (Fig. 5
A). The influx of Gr-1 CD11b  cells is independent of V 14
NKT cells because increased numbers of Gr-1 CD11b  cells
were detected in J 281 /  mice after islet transplantation (Fig.
5 C), suggesting that Gr-1 CD11b  cells are generated by
transplantation. However, IFN-  production by Gr-1 
CD11b  cells was dramatically augmented by a single injec-
Figure 3. Prevention of diabetes with transplantation of 200 syn-
geneic islets and anti–Gr-1 or anti-CD11b antibody treatment. STZ-
induced diabetic mice transplanted with 200 islets were injected intraportally 
with control antibody (A), anti–Gr-1 mAb (B), or anti-CD11b mAb (C).
Figure 4. Prevention of syngeneic islet graft failure by repeated 
 -GalCer treatment. (A) Cytokine production of V 14 NKT cells. 2   104 
purified liver V 14 NKT cells/well from mice injected i.p. one (closed bar) 
or three (open bar) times with  -GalCer or vehicle were cultured with 100 
ng/ml  -GalCer or 104 vehicle-pulsed DCs/well and measured for their 
cytokines by ELISA. Values represent mean   SD. (B and C) Rejection of 
islet graft by single  -GalCer stimulation. 400 syngenic islets were grafted 
into STZ-induced diabetic C57BL/6 mice treated with a single i.p. injection 
of vehicle (B) or 100  g/kg  -GalCer (C) at the time of islet transplantation. 
(D and E) Protection of islet graft failure by repeated  -GalCer stimulation. 
Mice transplanted with 200 syngenic islets were treated three times with 
vehicle (D) or 100  g/kg  -GalCer (E) on days 15, 11, and 7 before being 
injected with STZ 3 d before the transplantation. Individual lines represent 
the nonfasting plasma glucose levels of each animal. The asterisk indicates 
that the animal died because of severe diabetes.JEM VOL. 202, October 3, 2005 917
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tion of  -GalCer (Fig. 5 D) but diminished to a level equiva-
lent to the vehicle-treated control (Fig. 5 E) when repeated
injections of  -GalCer were given (Fig. 5 F). Thus, IFN- 
production by Gr-1 CD11b  cells is totally dependent on the
activation status of V 14 NKT cells. The findings on the pro-
tection of disease development by repeated  -GalCer injec-
tions were also reported in a type I diabetes model (17). It has
been reported that IFN-  is an essential molecule in the de-
struction of islets, causing the development of diabetes in a
mouse model of virus-induced insulin-dependent diabetes
mellitus (18). Furthermore, IFN-  has been shown to induce
nitric oxide–mediated toxicity to islet   cells in vitro in com-
bination with IL-1 (19). It is thus likely that IFN-  produced
by Gr-1 CD11b  cells might similarly affect islet   cells.
Overall, our data suggest that the modulation of V 14 NKT
cell function by repeated  -GalCer stimulation in vivo ma-
nipulates IFN-  production by Gr-1 CD11b  cells and pre-
vents immediate graft failure and the early loss of islet grafts,
thus contributing to successful pancreatic islet transplantation.
Concluding remarks
Our results obtained in a mouse model have important clini-
cal implications. Similar to V 14 NKT cells in mice, human
V 24 NKT cells also release large quantities of INF-  on ac-
tivation (20), suggesting that the early graft loss of islets in
humans is similarly mediated by V 24 NKT cells. If this as-
sumption is correct, treatment regimens aimed at the down-
regulation of INF-  production by human V 24 NKT cells
might help to prevent the early loss of islet grafts in clinical
settings, even though V 24 NKT cells are less frequent in
the human liver (21), and, thus, might help to increase the
efficiency of pancreatic islet transplants.
MATERALS AND METHODS
Animals. C57BL/6 mice were purchased from Charles River Laboratories
and C57BL/6 J 281 /  mice (10–15 wk old) raised in our facility were
used (9). C57BL/6 IFN- –deficient mice were provided by Y. Iwakura
(University of Tokyo, Tokyo, Japan) (22). Experimental plans were ap-
proved by the committee on institutional animal care and use at Fukuoka
University and RIKEN.
Diabetes induction. Diabetes was induced by an i.v. injection of 180
mg/kg STZ (Sigma-Aldrich) (23).
Islet isolation. Islets isolated by collagenase digestion were centrifuged in
Ficoll-Conray gradients (24, 25) and transplanted via the portal vein into
the liver of STZ-treated mice (26).
 -GalCer treatment.  -GalCer was synthesized in our laboratory (27).
Mice were injected i.p. one or three times with 100  g/kg  -GalCer or
0.025% vehicle (wt/vol) before islet transplantation.
Flow cytometry and staining. The following mAbs were used: anti–
mouse FcR II/III (2.4G2), FITC-conjugated anti-CD3  (145-2C11),
FITC- or PE-conjugated anti-CD11b (M1/70), allophycocyanin-conju-
gated anti–IFN-  (XMG1.2), allophycocyanin-conjugated anti–IL-4 (11B11),
PerCP-conjugated anti–Gr-1 (Rb6-8c5), PerCP-Cy5.5–anti–Gr-1 (86-8C5),
FITC–anti-CD11c (HL3), FITC–anti-CD86 (GL-1), FITC–anti–I-Ab
(AF6-120.1), and controls (BD Biosciences). FITC–anti-F4/80 (A3-1) and
FITC–anti-CD68 (FA-11) were obtained from SEROTEC. PE– -Gal-
Cer–CD1d tetramers were prepared as previously described (28). For intra-
cellular staining, cells were incubated with anti-FcR II/III and neutravidin
(Invitrogen), surface stained, fixed, permeabilized, stained with mAbs, and
analyzed on a flow cytometer (FACSCalibur; Becton Dickinson). 10,000
viable cells were analyzed.
Cell sorting and transfer. Hepatic mononuclear cells were prepared as
described previously (25). Gr-1 CD11b  cells and V 14 NKT cells were
sorted by MoFlo (DakoCytomation) with purity  99 and  98%, respec-
tively. Splenic DCs were purified by MACS with anti-CD11c–coupled
magnetic beads (Miltenyi Biotec) with purity  95%.
Antibody treatment. mAbs (10  g/mouse) against Gr-1 or CD11b
were i.p. injected into STZ-diabetic mice receiving 200 islets at the time
of transplantation.
Histology. The liver and pancreas from transplant recipients were fixed in
Bouin’s solution, processed, and embedded in paraffin. Sections were stained
with hematoxylin and eosin and aldehyde fuchsin. Immunohistochemistry
was performed by a streptavidin–biotin–peroxidase complex method (29).
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